RNXT
RenovoRx, Inc.
Biotechnology · Healthcare · United States
1.33
close · 2026-10-30
value
17
cheaper than peers17
quality
55
stronger fundamentals55
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | -15.2% | 41 |
| cash flow yield, latest year | -18.3% | 37 |
| earnings yield, latest year | -24.1% | 37 |
| earnings yield, 1 year ago | -30.1% | 37 |
| cash flow yield, 3 years ago | -14.7% | 36 |
| cash flow yield, 2 years ago | -17.1% | 36 |
| price to sales | 30.38× | 29 |
| price to book | 6.68× | 27 |
| earnings yield, 2 years ago | -74.4% | 23 |
| earnings yield, 3 years ago | -82.0% | 22 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 115.4% | 79 |
| debt to equity | 4.3% | 76 |
| operating margin | -368.4% | 38 |
| return on equity | -125.2% | 18 |
4 of 4 measures available
Facts
| market cap | $60M |
| free cash flow | -$6.6M |
| employees | 17 |
| first trade | 2021-08-26 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-31 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.32 | -0.40 | -0.99 | -1.09 |
| free cash flow | -$11.0M | -$9.1M | -$10.3M | -$8.8M |
| net income | -$11.2M | -$8.8M | -$10.2M | -$9.9M |
| revenue | $1.1M | $43,000 | $0 | $0 |
| unusual items | $915,000 | $1.8M | $1.7M | $0 |